NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: IN
Post# of 33
(Total Views: 179)
Posted On: 10/08/2019 4:28:22 PM
NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present at Second Annual Advances in Immuno-Oncology USA Congress and World Immunotherapy Congress
INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that its Co-Founder and CEO RJ Tesi, M.D., will present at the 2nd Annual Advances in Immuno-Oncology USA Congress taking place on October 8-9 in San Diego. In addition, Dr. Tesi and Director of Neuroscience CJ Barnum, Ph.D., will present at the World Immunotherapy Congress taking place from October 15-17 in Basel, Switzerland. “The immuno-oncology field is rapidly growing, and emerging new therapies are at the center of attention,” Dr. Tesi said in the news release. “With 30% of breast cancer patients being HER2+, trastuzumab has made significant strides in the treatment of breast cancer. Yet, many HER2+ breast cancer patients have shown resistance to the drug. In my presentation during the Advances in Immuno-Oncology USA Congress, I will address one of the reasons for the resistance – specifically the presence of the MUC4 biomarker – and how we may be able to use a soluble TNF inhibitor, such as our drug candidate INB03, to increase the efficacy of trastuzumab in those women who have shown resistance.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that its Co-Founder and CEO RJ Tesi, M.D., will present at the 2nd Annual Advances in Immuno-Oncology USA Congress taking place on October 8-9 in San Diego. In addition, Dr. Tesi and Director of Neuroscience CJ Barnum, Ph.D., will present at the World Immunotherapy Congress taking place from October 15-17 in Basel, Switzerland. “The immuno-oncology field is rapidly growing, and emerging new therapies are at the center of attention,” Dr. Tesi said in the news release. “With 30% of breast cancer patients being HER2+, trastuzumab has made significant strides in the treatment of breast cancer. Yet, many HER2+ breast cancer patients have shown resistance to the drug. In my presentation during the Advances in Immuno-Oncology USA Congress, I will address one of the reasons for the resistance – specifically the presence of the MUC4 biomarker – and how we may be able to use a soluble TNF inhibitor, such as our drug candidate INB03, to increase the efficacy of trastuzumab in those women who have shown resistance.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)INmune Bio Inc. (INMB) Stock Research Links
Scroll down for more posts ▼